About the ADVANCE Study - ARGENX 2682-0011
Clinical Trial for the treatment of ITP
The ADVANCE study is designed to assess how effective and safe the investigational study drug (efgartigimod) is compared to a placebo* as a possible treatment for adults living with primary ITP, primary being the absence of other causes or disorders associated with thrombocytopenia.
* A placebo is a dummy drug that has no active ingredient and is used to compare the effects of the investigational study drug. The placebo will look exactly like the investigational drug and will be administered through the vein the same way to make sure that no one, not even the study doctor, will know which drug has been assigned to whom.

Who is Eligible to Participate?
To join, you or someone you know must:
- Be at least 18 years old.
- Not be pregnant, not be lactating, and not be actively trying to get pregnant.
- Have been diagnosed with primary ITP for more than three (3) months.
- Meet other criteria which the study staff will discuss.
What to expect with the ADVANCE study
![]() | INFORMED CONSENT
| ![]() | SCREENING |
![]() | RANDOMIZATION | ![]() | STUDY LENGTH |
![]() | VISIT PROCEDURES
| ![]() | STUDY-RELATED EXPENSES |
What to expect with the ADVANCE study
INFORMED CONSENT
|
SCREENING |
RANDOMIZATION |
STUDY LENGTH |
VISIT PROCEDURES
|
STUDY-RELATED EXPENSES |
Seeking to address the needs of ITP patients
The ADVANCE clinical study was designed with input from patients and expert clinicians.
|
*Efgartigimod is an investigational product candidate, without approval by any regulatory body, and it is being studied in clinical trials as a therapeutic for ITP, among other indications.
Seeking to address the needs of ITP patients
The ADVANCE clinical study was designed with input from patients and expert clinicians.
|
*Efgartigimod is an investigational product candidate, without approval by any regulatory body, and it is being studied in clinical trials as a therapeutic for ITP, among other indications.